WO2004108157A8 - Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders - Google Patents
Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disordersInfo
- Publication number
- WO2004108157A8 WO2004108157A8 PCT/US2004/017049 US2004017049W WO2004108157A8 WO 2004108157 A8 WO2004108157 A8 WO 2004108157A8 US 2004017049 W US2004017049 W US 2004017049W WO 2004108157 A8 WO2004108157 A8 WO 2004108157A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gdf8
- myostatin
- corticosteroids
- inhibitors
- conjunction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002526669A CA2526669A1 (en) | 2003-06-02 | 2004-06-01 | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
EP04753802A EP1635870A2 (en) | 2003-06-02 | 2004-06-01 | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
MXPA05012965A MXPA05012965A (en) | 2003-06-02 | 2004-06-01 | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders. |
AU2004245025A AU2004245025A1 (en) | 2003-06-02 | 2004-06-01 | Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
JP2006515022A JP5110877B2 (en) | 2003-06-02 | 2004-06-01 | Use of myostatin (GDF8) inhibitors in combination with corticosteroids to treat neuromuscular disorders |
BRPI0410927-9A BRPI0410927A (en) | 2003-06-02 | 2004-06-01 | therapeutic and prophylactic methods for neuromuscular disorders |
NO20056252A NO20056252L (en) | 2003-06-02 | 2005-12-30 | Therapeutic and prophylactic methods for neuromuscular disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47460303P | 2003-06-02 | 2003-06-02 | |
US60/474,603 | 2003-06-02 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2004108157A2 WO2004108157A2 (en) | 2004-12-16 |
WO2004108157A3 WO2004108157A3 (en) | 2005-02-17 |
WO2004108157B1 WO2004108157B1 (en) | 2005-04-14 |
WO2004108157A8 true WO2004108157A8 (en) | 2006-11-16 |
Family
ID=33511616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/017049 WO2004108157A2 (en) | 2003-06-02 | 2004-06-01 | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
Country Status (16)
Country | Link |
---|---|
US (2) | US7785587B2 (en) |
EP (1) | EP1635870A2 (en) |
JP (2) | JP5110877B2 (en) |
KR (1) | KR20060026860A (en) |
CN (1) | CN1829532A (en) |
AU (1) | AU2004245025A1 (en) |
BR (1) | BRPI0410927A (en) |
CA (1) | CA2526669A1 (en) |
CO (1) | CO5660274A2 (en) |
EC (1) | ECSP066268A (en) |
MX (1) | MXPA05012965A (en) |
NO (1) | NO20056252L (en) |
RU (1) | RU2322261C2 (en) |
UA (1) | UA85055C2 (en) |
WO (1) | WO2004108157A2 (en) |
ZA (1) | ZA200510456B (en) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
CA2526669A1 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
CA2558478A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
CA2891010C (en) | 2004-07-23 | 2022-09-20 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
EA015534B1 (en) | 2005-04-25 | 2011-08-30 | Пфайзер Инк. | Antibodies to myostatin and methods of use thereof |
CA2538208A1 (en) | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
DK1915397T3 (en) * | 2005-08-19 | 2015-04-20 | Wyeth Llc | Antagonist AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8-ASSOCIATED DISEASES |
ES2533464T3 (en) * | 2005-10-06 | 2015-04-10 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
ME00380B (en) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Activin-actriia antagonists and uses for promoting bone growth |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
MX2008007324A (en) * | 2005-12-06 | 2009-03-04 | Amgen Inc | Uses of myostatin antagonists. |
WO2007114319A1 (en) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | Method for control of blood kinetics of antibody |
WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
EP2049664B1 (en) | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders |
PL2066695T3 (en) | 2006-09-05 | 2013-08-30 | Lilly Co Eli | Anti-myostatin antibodies |
EP4026553A1 (en) | 2006-12-18 | 2022-07-13 | Acceleron Pharma, Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
MX2009008222A (en) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Activin-actriia antagonists and uses for treating or preventing breast cancer. |
TWI432449B (en) | 2007-02-02 | 2014-04-01 | Acceleron Pharma Inc | Variants derived from actriib and uses therefor |
TW201808334A (en) | 2007-02-09 | 2018-03-16 | 艾瑟勒朗法瑪公司 | Pharmaceutical composition comprising an ActRIIa-Fc fusion protein; use of an ActRIIa-Fc fusion protein for treatment or prevention of cancer-related bone loss; use of an ActRIIa-Fc fusion protein for the treatment or prevention of multiple myeloma |
US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
WO2009008725A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
JP5706157B2 (en) | 2007-07-12 | 2015-04-22 | プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
US7960343B2 (en) | 2007-09-18 | 2011-06-14 | Acceleron Pharma Inc. | Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion |
EP2202245B1 (en) | 2007-09-26 | 2016-08-24 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
JP5600064B2 (en) | 2007-10-26 | 2014-10-01 | アカデミシュ ジーケンハウス ライデン | Means and methods for offsetting myopathy |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
PE20091163A1 (en) | 2007-11-01 | 2009-08-09 | Wyeth Corp | ANTIBODIES FOR GDF8 |
AU2009210872A1 (en) | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating DNA repeat instability associated genetic disorders |
SI2275443T1 (en) | 2008-04-11 | 2016-03-31 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
EP3363453A1 (en) | 2008-06-26 | 2018-08-22 | Acceleron Pharma Inc. | Soluble actriia as activin-actriia antagonist for use in treating anemia or bone-related disorders |
DK3750552T3 (en) | 2008-08-14 | 2023-07-24 | Acceleron Pharma Inc | GDF TRAPS |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
EA201100832A1 (en) | 2008-11-26 | 2011-12-30 | Амген Инк. | OPTIONS OF POLYPEPTIDES OF ACTIVIN IIB RECEPTOR AND THEIR APPLICATION |
CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
CA2759899A1 (en) | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
NO2424895T3 (en) | 2009-04-27 | 2018-02-03 | ||
JP5912078B2 (en) | 2009-06-08 | 2016-04-27 | アクセルロン ファーマ, インコーポレイテッド | Methods for increasing thermogenic adipocytes |
JP2012529294A (en) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ, インコーポレイテッド | Cleaved ActRIIB-Fc fusion protein |
US8945511B2 (en) * | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
KR20200086378A (en) * | 2009-09-09 | 2020-07-16 | 악셀레론 파마 인코포레이티드 | Actriib antagonists and dosing and uses thereof |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
ES2579311T3 (en) * | 2010-01-15 | 2016-08-09 | Rigel Pharmaceuticals, Inc. | Scan test using DEX and GDF8 |
US20110268736A1 (en) * | 2010-04-30 | 2011-11-03 | Children's Medical Center Corporation | Method for treating congenital myopathy |
JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
MX2013001845A (en) | 2010-08-16 | 2013-08-27 | Amgen Inc | Antibodies that bind myostatin, compositions and methods. |
JP2014502260A (en) | 2010-11-08 | 2014-01-30 | アクセルロン ファーマ, インコーポレイテッド | ACTRIIA binders and uses thereof |
TWI654204B (en) | 2010-11-30 | 2019-03-21 | 中外製藥股份有限公司 | Antibody with calcium-dependent antigen binding ability |
US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
WO2013112053A1 (en) | 2012-01-27 | 2013-08-01 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
US9506033B2 (en) | 2012-05-22 | 2016-11-29 | University Of Massachusetts | Compositions and methods for inducing myoblast differentiation and myotube formation |
WO2013186719A1 (en) * | 2012-06-15 | 2013-12-19 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
JP6774164B2 (en) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | Mouse FcγRII specific Fc antibody |
NZ705370A (en) | 2012-08-24 | 2018-06-29 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
RU2678117C2 (en) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Activin-actrii antagonists and uses thereof for treating bone and other disorders |
EA201591423A1 (en) | 2013-02-01 | 2016-01-29 | Санта Мария Биотерапевтикс, Инк. | INTRODUCTION OF ANTIBODIES TO ACTIVINE-A TO PATIENTS |
EP2968991A2 (en) * | 2013-03-15 | 2016-01-20 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
EP3783017A1 (en) | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
HUE052232T2 (en) | 2013-05-06 | 2021-04-28 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
TW201920262A (en) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | Anti-activin A antibodies and uses thereof |
PL3027642T3 (en) * | 2013-07-31 | 2021-01-11 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) constructs |
CN106795224B (en) | 2014-06-04 | 2021-05-18 | 阿塞勒隆制药公司 | Methods and compositions for treating conditions with follistatin polypeptides |
US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
MA40008A (en) | 2014-06-13 | 2021-05-05 | Acceleron Pharma Inc | ANTAGONIST ACTRII FOR THE TREATMENT AND PREVENTION OF SKIN ULCER IN A SUBJECT WITH ANEMIA |
MA41052A (en) | 2014-10-09 | 2017-08-15 | Celgene Corp | TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS |
EP4233889A3 (en) | 2014-12-03 | 2023-10-11 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
KR101860280B1 (en) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
AU2016238254B2 (en) | 2015-03-26 | 2022-05-05 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
EP3283519A1 (en) | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
DK3286206T3 (en) | 2015-04-22 | 2021-05-03 | Biogen Ma Inc | UNKNOWN HYBRID ACTRIIB-LIGAND-TRAP PROTEINS FOR THE TREATMENT OF MUSCLE WIND DISEASES |
KR20170074604A (en) | 2015-12-22 | 2017-06-30 | 삼성전자주식회사 | Composition for preventing or treating muscle wasting-related disease and use thereof |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
CN116284392A (en) | 2016-03-10 | 2023-06-23 | 艾科赛扬制药股份有限公司 | Activin type 2 receptor binding proteins and uses thereof |
WO2018025982A1 (en) | 2016-08-05 | 2018-02-08 | 中外製薬株式会社 | Composition for prophylaxis or treatment of il-8 related diseases |
CN111787981A (en) | 2018-03-01 | 2020-10-16 | 瑞泽恩制药公司 | Method of altering body composition |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US150577A (en) * | 1874-05-05 | Improvement in grain-separators | ||
US4370976A (en) * | 1980-06-03 | 1983-02-01 | Contour Fabricators, Inc. | Dynamic foam orthosis |
US5130141A (en) * | 1988-05-24 | 1992-07-14 | Law Peter K | Compositions for and methods of treating muscle degeneration and weakness |
US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
GB9211085D0 (en) * | 1992-05-23 | 1992-07-08 | Tippey Keith E | Electrical stimulation |
US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US6607884B1 (en) * | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
US6673534B1 (en) * | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
JPH09507829A (en) | 1993-03-19 | 1997-08-12 | ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | Growth differentiation factor-8 |
EP2272959A1 (en) * | 1993-05-12 | 2011-01-12 | Genetics Institute, LLC | BMP-11 compositions |
US5731415A (en) * | 1993-06-17 | 1998-03-24 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
DE69434739T2 (en) | 1993-08-26 | 2007-05-10 | Genetics Institute, LLC, Cambridge | Human bone morphogenetic proteins for use in neuronal degeneration |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US7332575B2 (en) * | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
CA2194660C (en) * | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
PT2045322E (en) | 1997-07-14 | 2015-10-16 | Université de Liège | Double-muscling in mammals |
US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
WO1999006559A1 (en) | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
AU8921698A (en) | 1997-08-29 | 1999-03-16 | Human Genome Sciences, Inc. | Follistatin-3 |
AU1276399A (en) | 1997-11-07 | 1999-05-31 | Genetics Institute Inc. | Neuronal uses of bmp-11 |
WO1999024618A1 (en) | 1997-11-10 | 1999-05-20 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
CA2319703C (en) | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
AU765214B2 (en) | 1998-05-06 | 2003-09-11 | Metamorphix International, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
US6660499B1 (en) | 1998-08-20 | 2003-12-09 | Regeneron Pharmaceuticals, Inc. | DCR5, a BMP-binding protein, and applications thereof |
WO2000043781A2 (en) | 1999-01-21 | 2000-07-27 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
TR200400621T2 (en) | 1999-07-20 | 2004-08-23 | Pharmexa A/S | A method for downregulating GDF-8 activity. |
AU2001241817A1 (en) | 2000-02-29 | 2001-09-12 | Zymogenetics Inc. | Kunitz domain polypeptide zkun8 |
US6649588B1 (en) * | 2000-10-05 | 2003-11-18 | North Shore - Long Island Jewish Research Institute | Inhibition of TGF-β and uses thereof |
US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
US6552172B2 (en) | 2001-08-30 | 2003-04-22 | Habto Biotech, Inc. | Fibrin nanoparticles and uses thereof |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
EP1572934A4 (en) | 2002-02-21 | 2007-12-19 | Wyeth Corp | Follistatin domain containing proteins |
EP1572909A4 (en) * | 2002-02-21 | 2007-06-06 | Wyeth Corp | A follistatin domain containing protein |
EP2192129A1 (en) | 2002-09-16 | 2010-06-02 | Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
CA2526669A1 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
US20060034831A1 (en) | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
MX2007011400A (en) | 2005-03-23 | 2007-10-11 | Wyeth Corp | Detection of gdf-8 modulating agents. |
CN101137906A (en) | 2005-03-23 | 2008-03-05 | 惠氏公司 | Detection of an immune response to gdf-8 modulating agents |
-
2004
- 2004-06-01 CA CA002526669A patent/CA2526669A1/en not_active Abandoned
- 2004-06-01 WO PCT/US2004/017049 patent/WO2004108157A2/en active Application Filing
- 2004-06-01 EP EP04753802A patent/EP1635870A2/en not_active Withdrawn
- 2004-06-01 BR BRPI0410927-9A patent/BRPI0410927A/en not_active IP Right Cessation
- 2004-06-01 MX MXPA05012965A patent/MXPA05012965A/en active IP Right Grant
- 2004-06-01 UA UAA200512673A patent/UA85055C2/en unknown
- 2004-06-01 US US10/858,353 patent/US7785587B2/en not_active Expired - Fee Related
- 2004-06-01 KR KR1020057023105A patent/KR20060026860A/en not_active Application Discontinuation
- 2004-06-01 RU RU2005141434/14A patent/RU2322261C2/en not_active IP Right Cessation
- 2004-06-01 JP JP2006515022A patent/JP5110877B2/en not_active Expired - Fee Related
- 2004-06-01 CN CNA2004800221348A patent/CN1829532A/en active Pending
- 2004-06-01 AU AU2004245025A patent/AU2004245025A1/en not_active Withdrawn
-
2005
- 2005-12-22 ZA ZA200510456A patent/ZA200510456B/en unknown
- 2005-12-30 NO NO20056252A patent/NO20056252L/en not_active Application Discontinuation
- 2005-12-30 CO CO05131698A patent/CO5660274A2/en not_active Application Discontinuation
-
2006
- 2006-01-02 EC EC2006006268A patent/ECSP066268A/en unknown
-
2007
- 2007-06-18 JP JP2007160708A patent/JP2007238631A/en active Pending
-
2010
- 2010-08-27 US US12/869,917 patent/US20100322942A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2526669A1 (en) | 2004-12-16 |
JP5110877B2 (en) | 2012-12-26 |
WO2004108157B1 (en) | 2005-04-14 |
WO2004108157A3 (en) | 2005-02-17 |
ZA200510456B (en) | 2009-05-27 |
ECSP066268A (en) | 2006-07-28 |
US20050014733A1 (en) | 2005-01-20 |
JP2007238631A (en) | 2007-09-20 |
US20100322942A1 (en) | 2010-12-23 |
CN1829532A (en) | 2006-09-06 |
RU2322261C2 (en) | 2008-04-20 |
US7785587B2 (en) | 2010-08-31 |
CO5660274A2 (en) | 2006-07-31 |
NO20056252L (en) | 2005-12-30 |
KR20060026860A (en) | 2006-03-24 |
RU2005141434A (en) | 2006-07-10 |
WO2004108157A2 (en) | 2004-12-16 |
EP1635870A2 (en) | 2006-03-22 |
UA85055C2 (en) | 2008-12-25 |
JP2006527193A (en) | 2006-11-30 |
AU2004245025A1 (en) | 2004-12-16 |
MXPA05012965A (en) | 2006-03-09 |
BRPI0410927A (en) | 2006-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004108157A3 (en) | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders | |
WO2005009349A3 (en) | Composition and method for treating neurological disorders | |
WO2007112345A8 (en) | Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders | |
TW200507830A (en) | Bronchodilating β -agonist compositions and methods | |
WO2003068171A3 (en) | Method and composition for treatment of inflammation and aids-associated neurological disorders | |
WO2005092009A3 (en) | Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders | |
WO2006020884A3 (en) | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors | |
WO2007112352A3 (en) | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders | |
MXPA05013900A (en) | Use of brimonidine for preventing and reducing the severity of stress-associated conditions. | |
WO2004089415A3 (en) | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | |
WO2005105780A3 (en) | Compositions useful as inhibitors of rock and other protein kinases | |
WO2004058700A3 (en) | Mitotic kinesin inhibitors | |
WO2007112357A3 (en) | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders | |
WO2007022408A3 (en) | Combination methods of saha and targretin for treating cancer | |
WO2006009975A3 (en) | Histamine to treat disorders affecting muscle function | |
WO2004062623A3 (en) | Method of treating functional bowel disorders | |
WO2004012762A3 (en) | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels | |
WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
GB2396108B (en) | Treatment of pain | |
WO2007044325A3 (en) | Apoe4 domain interaction inhibitors and methods of use thereof | |
WO2004071413A3 (en) | Method and composition for potentiating an opiate analgesic | |
WO2006002375A3 (en) | Method of treating ileus by pharmacological activation of cholinergic receptors | |
WO2007136615A3 (en) | Combination cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480022134.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
B | Later publication of amended claims |
Effective date: 20050201 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 172062 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2526669 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/012965 Country of ref document: MX Ref document number: 2006515022 Country of ref document: JP Ref document number: 12005502152 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057023105 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 543942 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004245025 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004245025 Country of ref document: AU Date of ref document: 20040601 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004753802 Country of ref document: EP Ref document number: 200510456 Country of ref document: ZA |
|
WWP | Wipo information: published in national office |
Ref document number: 2004245025 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2732/KOLNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005141434 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05131698 Country of ref document: CO Ref document number: 1200501950 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2006-008169 Country of ref document: CR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004753802 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057023105 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0410927 Country of ref document: BR |